Ipamorelin
Ipamorelin Acetate
The selective GH releaser
A pentapeptide ghrelin receptor agonist that triggers clean, selective growth hormone pulses without raising cortisol or prolactin. Ipamorelin is considered the most selective GH secretagogue available, making it the preferred choice for those prioritizing minimal side effects alongside GH optimization.
Key Benefits
Clean GH elevation without cortisol or prolactin spikes
Improved body composition (fat loss and lean mass retention)
Enhanced deep sleep quality and recovery
Increased bone mineral density over time
Dose-dependent response allowing precise titration
Mechanism of Action
How Ipamorelin works
Ipamorelin triggers growth hormone release through the ghrelin/GHS-R1a pathway:
- Ghrelin receptor (GHS-R1a) activation — binds the growth hormone secretagogue receptor on pituitary somatotrophs, triggering a calcium-dependent GH release pulse. Unlike GHRP-6 or GHRP-2, binding is highly selective with minimal off-target activation
- Selective GH release — does not significantly increase cortisol, ACTH, or prolactin at therapeutic doses. This selectivity distinguishes it from other GH secretagogues that activate broader hormonal cascades
- Amplified pulse amplitude — increases the height (amplitude) of each GH pulse while preserving natural pulse frequency. Complementary to CJC-1295, which extends pulse duration
- Dose-dependent linear response — GH output scales predictably with dose up to saturation, allowing precise titration based on individual response and genetic factors
Your Genetics & Ipamorelin
Genetic variants that affect your response
These SNPs determine how effectively Ipamorelin works for you specifically. A genetic peptide report identifies your variants before you start.
Variants in the growth hormone secretagogue receptor gene affect receptor density and signaling efficiency. Reduced GHSR expression means fewer targets for Ipamorelin, potentially blunting the GH pulse amplitude response.
The GHR exon 3 deletion (d3-GHR) increases downstream GH sensitivity. d3 carriers convert Ipamorelin-induced GH pulses into greater IGF-1 output, potentially achieving results at lower doses.
Variants affecting ghrelin gene expression alter baseline ghrelin levels. Since Ipamorelin competes at the same receptor, high endogenous ghrelin producers may experience different dose-response dynamics.
Somatostatin puts the brakes on GH release. Variants increasing somatostatin tone may partially counteract Ipamorelin's GH pulse, requiring timing optimization (evening dosing when somatostatin is naturally lower).
Which variants do you carry?
Upload your DNA data or order a kit to find out.
Evidence & Research
40+
Published studies
Published human or robust animal studies with clear mechanistic rationale
Common Stacks
Ipamorelin is commonly combined with:
Frequently Asked Questions
What is Ipamorelin used for?
Ipamorelin is used to stimulate natural growth hormone release for body composition, recovery, sleep quality, and anti-aging. Its key advantage over other GH secretagogues is selectivity — it raises GH without spiking cortisol or prolactin, making it one of the cleanest GH peptides available.
Why is Ipamorelin paired with CJC-1295?
Ipamorelin increases GH pulse amplitude (how high each pulse goes) while CJC-1295 extends pulse duration (how long each pulse lasts). Together they produce synergistic GH elevation through two different receptor pathways — GHRH receptor and ghrelin receptor — typically yielding 2-3x the output of either alone.
Does genetics affect Ipamorelin response?
Yes. GHSR variants determine how many ghrelin receptors Ipamorelin can activate. The GHR d3/fl polymorphism affects downstream GH sensitivity. Somatostatin gene variants influence how strongly your body counteracts GH pulses. A genetic peptide report identifies these factors for dose optimization.
Learn More About Ipamorelin
Personalize your protocol
Does Ipamorelin match your DNA?
Upload your existing genetic data or order a kit. Your report scores Ipamorelin against your unique genetic profile — CYP metabolism, receptor variants, pathway markers — in minutes.